Transmission of HIV-1 drug resistance in Benin could jeopardise future treatment options

Sexually Transmitted Infections

Volumn 88, Issue 3, 2012, Pages 179-183

  Chamberland, Annie ^a   Diabaté, Souleymane ^a   Sylla, Mohamed ^a   Anagounou, Séverin ^b   Geraldo, Nassirou ^b   Zannou, Djimon Marcel ^c   Labbé, Annie Claude ^a,d   Worobey, Michael ^e   Alary, Michel ^f,g,h   Tremblay, Cécile ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b Centre de santé communal de Cotonou 1   (Benin)

^c Centre national hospitalier universitaire   (Benin)

^d UNIVERSITY OF MONTREAL   (Canada)

^e The University of Arizona   (United States)

^f LAVAL UNIVERSITY   (Canada)

^g UNIVERSITÉ LAVAL   (Canada)

^h INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AGED; ALGORITHM; ANTIVIRAL RESISTANCE; ARTICLE; BENIN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHYLOGENY; POPULATION RESEARCH; PRIORITY JOURNAL; SEXUAL BEHAVIOR; TREATMENT PLANNING; UNINDEXED SEQUENCE; VIRUS ISOLATION; VIRUS TRANSMISSION;

ADULT; AGED; ANTI-HIV AGENTS; BENIN; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; MUTATION, MISSENSE; PHYLOGENY; PLASMA; RNA, VIRAL; SEQUENCE ANALYSIS, DNA;

EID: 84860329521     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sextrans-2011-050209     Document Type: Article

References (16)

1. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009;373:48-57.
2. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006;3:e124.
3. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1- infected adults in Cameroon: Open-label multicentre trial. Lancet 2004;364:29-34. (Pubitemid 38968622)
4. Montes B, Vergne L, Peeters M, et al. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004;35:329-36. (Pubitemid 38332792)
5. Turriziani O, Russo G, Lichtner M, et al. Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon. AIDS Res Hum Retroviruses 2008;24:781-5. (Pubitemid 351871669)
6. Lowndes CM, Alary M, Labbe AC, et al. Interventions among male clients of female sex workers in Benin, West Africa: An essential component of targeted HIV preventive interventions. Sex Transm Infect 2007;83:577-81. (Pubitemid 350290980)
7. Alary M, Mukenge-Tshibaka L, Bernier F, et al. Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993- 1999. AIDS 2002;16:463-70. (Pubitemid 34165379)
8. Lowndes CM, Alary M, Meda H, et al. Role of core and bridging groups in the transmission dynamics of HIV and STIs in Cotonou, Benin, West Africa. Sex Transm Infect 2002;78(Suppl 1):i69-77. (Pubitemid 34548002)
9. UNAIDS/WHO. Guidelines for Surveillance of HIV Drug Resistance. Geneva, Switzerland: WHO Library cataloguing-in-publication data, 2003:9.
10. Haidara A, Chamberland A, Sylla M, et al. High level of primary drug resistance in Mali. HIV Med 2010;11:404-11.
11. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009;17:138-45.
12. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
13. UNAIDS/WHO. Priority Interventions, HIV/AIDS Prevention, Treatment and Care in the Health Sector. Veriosn 1. Geneva, Switzerland: WHO, 2010:126.
14. Asahchop EL, Oliveira M, Wainberg MA, et al. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother 2011;55:600-7.
15. Xu HT, Asahchop EL, Oliveira M, et al. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011;85:11300-8.
16. Derache A, Maiga AI, Traore O, et al. Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008;62:456-63.